A Phase 1 interventional study of LY2963016 and Lantus in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study involves 2 single injections of LY2963016 and 2 single injections of Lantus. There will be at least 6 days between each injection.
The study will compare LY2963016 to Lantus at two different doses.
This study is approximately 10 weeks long, not including screening. Screening is required within 4 weeks of the start of the study.
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 0.3 units/kilogram (U/kg) subcutaneous dose of LY2963016
Drug: LY2963016
Single 0.3 U/kg subcutaneous dose of Lantus
Drug: Lantus
Single 0.6 U/kg subcutaneous dose of LY2963016
Drug: LY2963016
Single 0.6 U/kg subcutaneous dose of Lantus
Drug: Lantus
Administered subcutaneously
Administered subcutaneously
Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)]
Results for LY2936016 treatment arms provide the AUC(0-∞) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-∞) for Lantus.
Time frame: Predose up to 24 hours after administration of study drug
Pharmacokinetics: Maximum Serum LY2963016 or Lantus Concentration (Cmax)
Time frame: Predose up to 24 hours after administration of study drug
Pharmacokinetics: Area Under the Serum Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 or Lantus
Results for LY2936016 treatment arms provide the AUC(0-24) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-24) for Lantus.
Time frame: Predose up to 24 hours after administration of study drug
Pharmacokinetics: Area Under the Serum Concentration-Time Curve (AUC) From Time Zero to Last Measured Concentration Value [AUC(0-tlast)] of LY2963016 or Lantus
Results for LY2936016 treatment arms provide the AUC(0-tlast) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-tlast) for Lantus.
Time frame: Predose up to 24 hours after administration of study drug
Maximum Glucose Infusion Rate (Rmax)
Rmax is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.
Time frame: Postdose up to 24 hours after administration of study drug
Total Amount of Glucose Infused (Gtot)
Gtot is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.
Time frame: Postdose up to 24 hours after administration of study drug
| Milestone | 0.3 U/kg LY, 0.6 U/kg LY, 0.3 U/kg Lantus, 0.6 U/kg Lantus | 0.6 U/kg LY, 0.6 U/kg Lantus, 0.3 U/kg LY, 0.3 U/kg Lantus | 0.3 U/kg Lantus, 0.3 U/kg LY, 0.6 U/kg Lantus, 0.6 U/kg LY | 0.6 U/kg Lantus, 0.3 U/kg Lantus, 0.6 U/kg LY, 0.3 U/kg LY |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Received at least 1 dose of study drug | 6 | 6 | 6 | 6 |
| Completed | 6 | 6 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 0.3 U/kg LY, 0.6 U/kg LY, 0.3 U/kg Lantus, 0.6 U/kg Lantus | 0.6 U/kg LY, 0.6 U/kg Lantus, 0.3 U/kg LY, 0.3 U/kg Lantus | 0.3 U/kg Lantus, 0.3 U/kg LY, 0.6 U/kg Lantus, 0.6 U/kg LY | 0.6 U/kg Lantus, 0.3 U/kg Lantus, 0.6 U/kg LY, 0.3 U/kg LY |
|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 |
| Completed | 6 | 5 | 6 | 6 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Milestone | 0.3 U/kg LY, 0.6 U/kg LY, 0.3 U/kg Lantus, 0.6 U/kg Lantus | 0.6 U/kg LY, 0.6 U/kg Lantus, 0.3 U/kg LY, 0.3 U/kg Lantus | 0.3 U/kg Lantus, 0.3 U/kg LY, 0.6 U/kg Lantus, 0.6 U/kg LY | 0.6 U/kg Lantus, 0.3 U/kg Lantus, 0.6 U/kg LY, 0.3 U/kg LY |
|---|---|---|---|---|
| Started | 6 | 5 | 6 | 6 |
| Completed | 6 | 5 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | 0.3 U/kg LY, 0.6 U/kg LY, 0.3 U/kg Lantus, 0.6 U/kg Lantus | 0.6 U/kg LY, 0.6 U/kg Lantus, 0.3 U/kg LY, 0.3 U/kg Lantus | 0.3 U/kg Lantus, 0.3 U/kg LY, 0.6 U/kg Lantus, 0.6 U/kg LY | 0.6 U/kg Lantus, 0.3 U/kg Lantus, 0.6 U/kg LY, 0.3 U/kg LY |
|---|---|---|---|---|
| Started | 6 | 5 | 6 | 6 |
| Completed | 6 | 5 | 6 | 6 |
| Not completed | 0 | 0 | 0 | 0 |
Results for LY2936016 treatment arms provide the AUC(0-∞) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-∞) for Lantus.
| picomoles*hour per liter (pmol*h/L) | 0.3 U/kg LY2963016 | 0.6 U/kg LY2963016 | 0.3 U/kg Lantus | 0.6 U/kg Lantus |
|---|---|---|---|---|
| Pharmacokinetics: Area Under the Serum LY2963016 or Lantus Concentration-Time Curve (AUC) From Zero to Infinity [AUC(0-∞)] | 2330 ± 39 | 4470 ± 15 | 2390 ± 33 | 4310 ± 51 |
| picomoles per liter (pmol/L) | 0.3 U/kg LY2963016 | 0.6 U/kg LY2963016 | 0.3 U/kg Lantus | 0.6 U/kg Lantus |
|---|---|---|---|---|
| Pharmacokinetics: Maximum Serum LY2963016 or Lantus Concentration (Cmax) | 108 ± 20 | 180 ± 28 | 105 ± 33 | 174 ± 38 |
Results for LY2936016 treatment arms provide the AUC(0-24) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-24) for Lantus.
| picomoles*hour per liter (pmol*h/L) | 0.3 U/kg LY2963016 | 0.6 U/kg LY2963016 | 0.3 U/kg Lantus | 0.6 U/kg Lantus |
|---|---|---|---|---|
| Pharmacokinetics: Area Under the Serum Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 or Lantus | 1730 ± 20 | 3160 ± 27 | 1690 ± 30 | 2940 ± 45 |
Results for LY2936016 treatment arms provide the AUC(0-tlast) data for LY2936016, while the results for Lantus treatment arms provide the AUC(0-tlast) for Lantus.
| picomoles*hour per liter (pmol*h/L) | 0.3 U/kg LY2963016 | 0.6 U/kg LY2963016 | 0.3 U/kg Lantus | 0.6 U/kg Lantus |
|---|---|---|---|---|
| Pharmacokinetics: Area Under the Serum Concentration-Time Curve (AUC) From Time Zero to Last Measured Concentration Value [AUC(0-tlast)] of LY2963016 or Lantus | 1730 ± 20 | 3160 ± 27 | 1670 ± 28 | 2940 ± 45 |
Rmax is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.
| milligrams/kilograms/minute (mg/kg/min) | 0.3 U/kg LY2963016 | 0.6 U/kg LY2963016 | 0.3 U/kg Lantus | 0.6 U/kg Lantus |
|---|---|---|---|---|
| Maximum Glucose Infusion Rate (Rmax) | 1.81 ± 100 | 3.05 ± 59 | 1.70 ± 92 | 3.25 ± 54 |
Gtot is used to measure the study drug action over time as measured by the euglycaemic clamp procedure. During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.
| milligrams per kilograms (mg/kg) | 0.3 U/kg LY2963016 | 0.6 U/kg LY2963016 | 0.3 U/kg Lantus | 0.6 U/kg Lantus |
|---|---|---|---|---|
| Total Amount of Glucose Infused (Gtot) | 1060 ± 178 | 2260 ± 80 | 1050 ± 130 | 2590 ± 62 |
Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.3 U/kg LY2963016 | — | 0/23 (0%) | 4/23 (17.4%) |
| 0.6 U/kg LY2963016 | — | 0/24 (0%) | 10/24 (41.7%) |
| 0.3 U/kg Lantus | — | 0/23 (0%) | 10/23 (43.5%) |
| 0.6 U/kg Lantus | — | 1/24 (4.2%) | 12/24 (50%) |
| Event | 0.3 U/kg LY2963016 | 0.6 U/kg LY2963016 | 0.3 U/kg Lantus | 0.6 U/kg Lantus |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/23 | 0/24 | 0/23 | 1/24 |
| Event | 0.3 U/kg LY2963016 | 0.6 U/kg LY2963016 | 0.3 U/kg Lantus | 0.6 U/kg Lantus |
|---|---|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 1/23 | 1/24 | 4/23 | 2/24 |
| Post procedural swellingInjury, poisoning and procedural complications | 1/23 | 2/24 | 3/23 | 1/24 |
| Application site haematomaGeneral disorders | 1/23 | 1/24 | 2/23 | 3/24 |
| VomitingGastrointestinal disorders | 0/23 | 2/24 | 0/23 | 1/24 |
| DizzinessNervous system disorders | 0/23 | 0/24 | 1/23 | 2/24 |
| Abdominal distensionGastrointestinal disorders | 0/23 | 0/24 | 1/23 | 0/24 |
| NauseaGastrointestinal disorders | 0/23 | 0/24 | 1/23 | 0/24 |
| Joint swellingMusculoskeletal and connective tissue disorders | 0/23 | 0/24 | 1/23 | 0/24 |
| HeadacheNervous system disorders | 0/23 | 1/24 | 1/23 | 0/24 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/23 | 0/24 | 1/23 | 1/24 |
Participants who received at least one dose of study drug.
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 32.1 ± 7.7 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 4 |
| Male | 20 |
| Race/Ethnicity, Customized(participants) | All Participants |
|---|---|
| Asian | 24 |
| Region of Enrollment(participants) | All Participants |
|---|---|
| Singapore | 24 |
The record gives a start of Jul 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine